Harvard Bioscience enters retention agreement with interim CFO Mark Frost

Published 13/08/2025, 21:46
Harvard Bioscience enters retention agreement with interim CFO Mark Frost

Harvard Bioscience, Inc. (NASDAQ:HBIO) announced Tuesday it has entered into a retention letter agreement with Mark Frost, the company’s Interim Chief Financial Officer. According to a statement in a recent SEC filing, the agreement makes Mr. Frost eligible for a cash bonus of $100,000 if he remains employed through the successful refinancing of the company’s existing term loan and senior revolving credit facility before March 15, 2026.

The retention bonus replaces a previous cash bonus of $50,000 that was outlined in Mr. Frost’s offer letter dated April 10, 2025. To receive the bonus, Mr. Frost must continue his employment through the refinancing date and, unless terminated without cause, through the retention date.

The agreement also details certain payments and benefits if Mr. Frost’s employment is terminated without cause before the retention date. In that scenario, he would receive his base salary and the company’s portion of COBRA health insurance premiums for five months following the termination, contingent on signing a general release of claims.

This information is based on a press release statement included in the company’s Form 8-K filed with the Securities and Exchange Commission. Harvard Bioscience is incorporated in Delaware and its common stock is listed on the NASDAQ Stock Market under the symbol HBIO.

In other recent news, Harvard Bioscience reported its Q2 2025 earnings, showing mixed results. The company achieved a revenue of $20.5 million, which did not meet the forecasted $21.4 million. Additionally, the earnings per share (EPS) was reported at -$0.01, falling short of the expected -$0.005. During the earnings call, the company emphasized its strategic initiatives and cost reduction efforts. Despite these financial results, the stock demonstrated resilience. These developments are part of the company’s ongoing efforts to navigate market challenges. Investors will be closely monitoring how Harvard Bioscience’s strategies impact future financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.